Introduction: This report describes the case of a male patient with pituitary macroadenoma treated with the artemisinin analog artemether. Patient and Methods: A 75 year-old male patient presented with vision, hearing, and locomotion-related problems. Artemether was administered orally to the patient over a period of 12 months. Results: Although the tumor remained consistent in size, CT scan shows a reduction in its density, and clinically, the related symptoms and signs resolved significantly as therapy progressed. Discussion: Overall, the artemether treatment was beneficial in improving the patient's quality of life. Artemether and other artemisinin analogs offer promise for cancer therapy.
Kreutzer J, Fahlbusch R. Diagnosis and treatment of pituitary tumors. Curr Opin Neurol.2004;17:693-703.
2.
Johnson MD, Woodburn CJ, Vance ML. Quality of life in patients with a pituitary adenoma. Pituitary. 2003;6:81-87.
3.
Senovilla L, Nunez L, de Campos JM, et al. Multifunctional cells in human pituitary adenomas: implications for paradoxical secretion and tumorigenesis. J Clin Endocrinol Metab.2004; 89:4545-4552.
4.
Yildiz F, Zorlu F, Erbas F, Atahan L. Radiotherapy in the management of giant pituitary adenomas. Radiother Oncol.1999; 32:233-237.
5.
Park P, Chandler WF, Barkan AL, et al. The role of radiation therapy after surgical resection of nonfunctional pituitary macroadenomas. Neurosurg.2004;55:100-106.
6.
Dekkers OM, Pereira AM, Roelfsema F, et al. Observation alone after transsphenoidal surgery for non-functioning pituitary macroadenoma. J Clin Endocrinol Metab.2006;91:1796-1801.
7.
Sassolas G, Trouillas J, Treluyer C, Perrin G. Management of nonfunctioning pituitary adenomas. Acta Endocrinol.1993;129 (Suppl):21-26.
Lai H, Singh NP. Selective cancer cell cytotoxicity from exposure to dihydroartemisinin and holotransferrin. Cancer Lett.1995;91:41-46.
10.
Singh NP, Lai H. Selective toxicity of dihydroartemisinin and holotransferrin toward human breast cancer cells. Life Sci.2001;70:49-56.
11.
Peys E, Vandenkerckhove J, Van Hemel J, Sas B. Intermediate term toxicity of repeated orally administered doses of the anti malarial beta-artemether in dogs. Exp Toxicol Pathol.2006;57: 299-304.
12.
Utzinger J, Xiao SH, N'Goran EK, Bergquist R, Tanner M. The potential of artemether for the control of schistosomiasis. Int J Parasitol.2001;31:1549-1562.
13.
Utzinger J, N'Goran E, N'Dri A, Lengeler C, Shuhua X, Tanner M. Oral artemether for prevention of infection: randomised controlled trial. Lancet. 2000;355:1320-1325.
14.
Xiao S, Yang Y, You Q, et al. Potential long-term toxicity of repeated orally administered doses of artemether in rats. Am J Trop Med Hyg.2002;66:30-34.
15.
Murray RA, Maheshwari HG, Russell EJ, Bauman G. Pituitary hypoplasia in patients with a mutation in the growth hormone–releasing hormone receptor gene. Am J Neuroradiol.2000;21:685-689.
16.
Moore JC, Lai H, Li JR, McDougall JA, Singh NP, Chou CK. Oral administration of dihydroartemisinin and ferrous sulfate retarded implanted fibrosarcoma growth in the rat. Cancer Lett.1995;98:83-87.
17.
Efferth T, Dunstan H, Sauerbrey A, Miyachi H, Chitambar CR. The anti-malarial artesunate is also active against cancer. Int J Oncol.2001;18:767-773.
18.
Singh NP, Verma KB. Case report of a laryngeal squamous cell carcinoma treated with artesunate. Arch Oncol.2002;10: 279-280.
19.
Berger TG, Dieckmann D, Efferth T, et al. Artesunate in the treatment of metastatic uveal melanoma-first experiences. Oncol Rep.2005;14:1599-1603.
20.
Singh NP, Lai H. Artemisinin induces apoptosis in human cancer cells. AntiCancer Res.2004;24:2277-2280.
21.
Ezzat S, Asa SL, Couldwell WT, et al. The prevalence of pituitary adenomas: a systematic review. Cancer. 2004;101:613-619.
22.
Feldkamp J, Santen R, Harms E, Aulich A, Modder U, Scherbaum WA. Incidentally discovered pituitary lesions: high frequency of macroadenomas and hormone-secreting adenomas—results of a prospective study. Clin Endocrinol (Oxf). 1999;51:109-113.
23.
Arita K, Tominaga A, Sugiyama K, et al. Natural course of incidentally found nonfunctioning pituitary adenoma, with special reference to pituitary apoplexy during follow-up examination. J Neurosurg.2006;104:884-891.
24.
Kabil MS, Ebv JB, Shahinian HK. Fully endoscopic endonasal vs. transseptal transsphenoidal pituitary surgery. Minim Invasive Neurosurg.2005;48:348-354.
25.
Zaugg M, Adaman O, Pescia R, Landolt AM. External irradiation of macroinvasive pituitary adenomas with telecobalt: a retrospective study with long-term follow-up in patients irradiated with doses mostly of between 40-45 Gy. Int J Radiat Oncol Biol Phys.1995;32:671-680.
